menu
    • menu
    [{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Protein Sciences Corporation"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Recombinant human glutamic acid decarboxylase","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ ICON","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ ICON"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GAD65-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAD65-Alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GAD65-Alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Recombinant Human Glutamic Acid Decarboxylase","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Diamyd Medical AB \/ JDRF","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ JDRF"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Recombinant Human Glutamic Acid Decarboxylase","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"DiaUnion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"Recombinant Human Glutamic Acid Decarboxylase","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ DiaUnion","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ DiaUnion"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Colecalciferol","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Diamyd Medical AB \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Diamyd Medical AB

    Menu

    Diamyd Medical AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diamyd Medical Pursues Accelerated Approval for Type 1 Diabetes Precision Medicine

                            Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diamyd Medical Receives Second FDA Fast Track Designation for Diamyd® in Type 1 Diabetes

                            Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 18, 2024

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Recruitment Milestone Reached in Diamyd® Phase 3 Trial

                            Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 12, 2024

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

                            Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 15, 2024

                            Lead Product(s) : rhGAD65,Vitamin D3

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Glutamic Acid Decarboxylase

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : DiaUnion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Diamyd Medical Partners with DiaUnion to Recruit Participants for Type 1 Diabetes Prevention Trial

                            Details : The partnership aims to identify participants for the DiaPrecise trial, an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd (recombinant human glutamic acid decarboxylase) in children at risk ...

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 07, 2023

                            Lead Product(s) : Recombinant Human Glutamic Acid Decarboxylase

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : DiaUnion

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Glutamic Acid Decarboxylase

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Registrational Phase III Trial in Type 1 Diabetes with Diamyd® Expands to the US

                            Details : Diamyd® is an antigen-specific immunotherapy for the treatment of autoimmune diabetes. Diamyd® is based on the protein GAD65, an endogenous antigen involved in the pathology of autoimmune diabetes.

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 05, 2023

                            Lead Product(s) : Recombinant Human Glutamic Acid Decarboxylase

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Glutamic Acid Decarboxylase

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : JDRF

                            Deal Size : $5.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Diamyd Medical Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes

                            Details : The collaboration aims to support Diamyd Medical's ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd (recombinant human glutamic acid decarboxylase), an antigen-specific immunotherapy for the preservation of endogeno...

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : Recombinant Human Glutamic Acid Decarboxylase

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : JDRF

                            Deal Size : $5.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GAD65-Alum,Vitamin D

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

                            Details : Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in Company's Europ...

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 27, 2022

                            Lead Product(s) : GAD65-Alum,Vitamin D

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GAD65-Alum,Vitamin D

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Updated Results From Clinical Trial With Diamyd® Presented Today At Diabetes Conference

                            Details : The diabetes vaccine Diamyd® (GAD-alum) is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical tria...

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 20, 2022

                            Lead Product(s) : GAD65-Alum,Vitamin D

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GAD-alum,Vitamin D

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Promising Topline Results for Intralymphatic Diamyd® in Patients With LADA

                            Details : Primary endpoints of safety and tolerability were met in Phase II clinical trial GADinLADA, in which diabetes vaccine Diamyd (GAD-alum) was administered directly into lymph node of 14 patients aged 30 to 70 years with autoimmune form of diabetes called L...

                            Brand Name : Diamyd

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 07, 2022

                            Lead Product(s) : GAD-alum,Vitamin D

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth